SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Raymond James Cuts Alnylam Price Target to $315, Downgrades Rating

Raymond James lowered its Alnylam Pharmaceuticals price target to $315 from $420 and cut its rating to Outperform from Strong Buy.

ALNY

Related stories